OPORFOPEN ORPHAN PLC.

About OPEN ORPHAN PLC. (OPORF)

OPEN ORPHAN PLC. (OPORF) is a Biotechnology company headquartered in London, ENG, United Kingdom whose shares trade over-the-counter on the Pink tier.

Open Orphan is a rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services and viral laboratory services. It has Europe's only 24-bedroom quarantine clinic with onsite virology lab in Queen Mary's Hospital London. hVIVO supports product development for customers developing antivirals, vaccines and respiratory therapeutics, all particularly relevant and topical in the environment of heightened awareness in 2020. The company also has a leading portfolio of 8 viral challenge study models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD viral challenge models. No other company in the world has such a portfolio, with only two competitors globally having 1 challenge study model each.

OPORF key facts

Ticker symbol

OPORF

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

London, ENG, United Kingdom

Country of incorporation

GB

Estimated market cap

$160.84M (as of May 13, 2025)

Shares outstanding

670,187,313

Reporting standard

International Reporting: LSE - London Stock Exchange

Audit status

Audited

Fiscal year end

12/31

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with O